[go: up one dir, main page]

NO20084912L - Bisykliske derivater som CETP-inhibitorer - Google Patents

Bisykliske derivater som CETP-inhibitorer

Info

Publication number
NO20084912L
NO20084912L NO20084912A NO20084912A NO20084912L NO 20084912 L NO20084912 L NO 20084912L NO 20084912 A NO20084912 A NO 20084912A NO 20084912 A NO20084912 A NO 20084912A NO 20084912 L NO20084912 L NO 20084912L
Authority
NO
Norway
Prior art keywords
cetp inhibitors
bicyclic derivatives
cetp
bicyclic
compounds
Prior art date
Application number
NO20084912A
Other languages
English (en)
Inventor
Eiji Kawahara
Osamu Ohmori
Ichiro Umemura
Yuki Iwaki
Masashi Kishida
Naoko Matsuura
Hidetomo Imase
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084912L publication Critical patent/NO20084912L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det beskrives nye forbindelser med formel (I) og farmasøytisk akseptable blandinger derav, der alle variabler er definert i teksten. Det beskrives videre anvendelse av forbindelsene for behandling eller forsinkelse av progresjonen for sykdommer der CETP er involvert.
NO20084912A 2006-05-10 2008-11-21 Bisykliske derivater som CETP-inhibitorer NO20084912L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21
PCT/EP2007/004058 WO2007128568A1 (en) 2006-05-10 2007-05-08 Bicyclic derivatives as cetp inhibitors

Publications (1)

Publication Number Publication Date
NO20084912L true NO20084912L (no) 2009-02-03

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084912A NO20084912L (no) 2006-05-10 2008-11-21 Bisykliske derivater som CETP-inhibitorer

Country Status (17)

Country Link
US (2) US8232403B2 (no)
EP (1) EP2024356A1 (no)
KR (1) KR101172120B1 (no)
AR (1) AR060873A1 (no)
AU (1) AU2007247385B2 (no)
CA (1) CA2650954C (no)
CL (1) CL2007001325A1 (no)
CR (1) CR10420A (no)
EC (1) ECSP088891A (no)
GT (1) GT200800242A (no)
IL (1) IL195010A0 (no)
MA (1) MA30427B1 (no)
MX (1) MX2008014284A (no)
NO (1) NO20084912L (no)
TN (1) TNSN08444A1 (no)
TW (1) TW200813009A (no)
WO (1) WO2007128568A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) * 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
CA2634833A1 (en) * 2005-12-29 2007-07-05 Novartis Ag Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
CA2650954C (en) * 2006-05-10 2014-02-11 Novartis Ag Bicyclic derivatives as cetp inhibitors
CA2650515A1 (en) * 2006-05-11 2007-11-22 Novartis Ag Benzylamine derivatives as cetp inhibitors
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
WO2008129951A1 (ja) * 2007-04-13 2008-10-30 Kowa Company, Ltd. 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5478508B2 (ja) 2008-11-28 2014-04-23 興和株式会社 ｔｒａｎｓ−｛４−［（アルキルアミノ）メチル］シクロヘキシル｝酢酸エステルの製造方法
WO2011028947A2 (en) * 2009-09-03 2011-03-10 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US9867811B2 (en) * 2011-07-08 2018-01-16 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
CN103827105B (zh) 2011-08-18 2016-08-17 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(cetp)抑制剂的取代的杂环胺化合物
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
RU2015123632A (ru) * 2012-11-19 2017-01-10 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции ингибиторов сетр
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
EP3024492A2 (en) 2013-07-25 2016-06-01 Novartis AG Bioconjugates of synthetic apelin polypeptides
EP3247405B1 (en) 2015-01-23 2019-07-17 Novartis AG Synthetic apelin fatty acid conjugates with improved half-life
WO2019238786A1 (en) 2018-06-12 2019-12-19 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (sting)
US20230076506A1 (en) * 2019-12-11 2023-03-09 Ryvu Therapeutics S.A. Heterocyclic compounds as modulators of stimulator of interferon genes (sting)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583183B2 (en) 1999-09-23 2003-06-24 Pharmacia Corporation Substituted n-phenyl-n-fused-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
JP2004505942A (ja) 2000-08-07 2004-02-26 ニューロゲン　コーポレイション Ｇａｂａａ受容体の配位子としての複素環式化合物
AU2003261826B2 (en) 2002-08-30 2006-02-02 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
JP2006521344A (ja) 2003-03-28 2006-09-21 ファイザー・プロダクツ・インク アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CA2562082C (en) 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
CA2589322A1 (en) 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US8358384B2 (en) 2005-01-06 2013-01-22 Thomson Licensing Reduced rainbow artifacts in digital light projection systems
CN101218497B (zh) 2005-07-07 2012-04-25 索尼株式会社 利用瞬逝光的物质信息获取方法和物质信息测量装置、以及碱基序列确定方法和装置
WO2007008899A2 (en) 2005-07-11 2007-01-18 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
JP4981814B2 (ja) 2005-12-28 2012-07-25 ドクター・レディーズ・ラボラトリーズ・リミテッド 選択的なベンジルアミン誘導体およびコレステロールエステル転写タンパク質抑制剤としてのその有用性
CA2634833A1 (en) 2005-12-29 2007-07-05 Novartis Ag Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
CA2650954C (en) * 2006-05-10 2014-02-11 Novartis Ag Bicyclic derivatives as cetp inhibitors
CA2650515A1 (en) 2006-05-11 2007-11-22 Novartis Ag Benzylamine derivatives as cetp inhibitors
BRPI0718399A2 (pt) 2006-11-15 2014-03-11 Novartis Ag Derivados heterocíclicos como inibidores de cetp
CA2668634A1 (en) 2006-11-15 2008-05-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP2024356A1 (en) 2009-02-18
MX2008014284A (es) 2008-11-18
AR060873A1 (es) 2008-07-16
US20090227580A1 (en) 2009-09-10
CL2007001325A1 (es) 2008-07-18
KR101172120B1 (ko) 2012-08-10
US8410275B2 (en) 2013-04-02
ECSP088891A (es) 2008-12-30
US8232403B2 (en) 2012-07-31
MA30427B1 (fr) 2009-05-04
WO2007128568A1 (en) 2007-11-15
AU2007247385B2 (en) 2011-07-14
AU2007247385A1 (en) 2007-11-15
TNSN08444A1 (en) 2010-04-14
GT200800242A (es) 2009-04-29
TW200813009A (en) 2008-03-16
KR20090017580A (ko) 2009-02-18
CA2650954C (en) 2014-02-11
CA2650954A1 (en) 2007-11-15
IL195010A0 (en) 2009-08-03
US20120225874A1 (en) 2012-09-06
CR10420A (es) 2009-02-02

Similar Documents

Publication Publication Date Title
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20090628L (no) Pyridizinon derivativater
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20061454L (no) Compounds having CRTH2 antagonist activity
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20092692L (no) MAPK/ERK kinaseinhibitorer
NO20090295L (no) Substituerte heteroarylderivater
NO20066055L (no) Pyridinderivater
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20090756L (no) Amino-piperidinderivater som CETP-inhibitorer
CL2008002954A1 (es) Compuestos derivados de 1,2,3,3a,3b,4,5,7,10,10a,10b,11,12,12a-tetradecahidrociclopenta-(5,6)nafto-(1,2-f)indazol heterociclo o carbociclo sustituido; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de asma, epoc, rinits alergica.
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20082096L (no) Azaindol-2-karboksamidderivativer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application